Pharma BD Deal Intelligence
A $16B leg of a multi-way GSK-Novartis asset swap that handed Novartis the GSK oncology portfolio while GSK took Novartis's vaccines business in return. A rare mega-swap where both sides got exactly the therapeutic focus they wanted, without a traditional bidding war or premium.
Multi-leg asset swap between GSK and Novartis announced April 22, 2014. Leg 1: GSK acquired Novartis vaccines business (excluding flu vaccines) for $7.1B. Leg 2: Novartis acquired GSK oncology portfolio (including marketed and pipeline assets) for $16B. Leg 3: GSK and Novartis combined their consumer healthcare businesses into a new joint venture (GSK 63.5%, Novartis 36.5%). Total deal value approximately $20B+. The swap fundamentally reshaped both companies strategic profiles, with GSK doubling down on vaccines/consumer and Novartis concentrating on innovative pharmaceuticals.
$100.0B Global Oncology Market (2014) · $16B Novartis Paid for GSK Oncology
In the reverse leg of the deal, Novartis acquired GSK's oncology portfolio for $16B, gaining marketed drugs (Votrient, Mekinist, Tafinlar) and pipeline assets. This allowed GSK to exit oncology and focus on vaccines/consumer health/respiratory, while Novartis consolidated its position as a top-3 oncology company.
Key assets transferred to Novartis included: Tafinlar (dabrafenib, BRAF inhibitor) and Mekinist (trametinib, MEK inhibitor) for melanoma, Votrient (pazopanib) for RCC/sarcoma, and multiple pipeline programs. The Tafinlar+Mekinist combination became a major franchise for Novartis in BRAF-mutant melanoma and NSCLC, generating $2B+ in annual sales.
$26.0B Global Vaccines Market (2014) · $7.1B GSK Paid for Novartis Vaccines
GSK acquired Novartis's vaccines division (excluding flu vaccines) for $7.1B as part of the transformative 2014 three-part asset swap. Key vaccine assets included Bexsero (meningococcal B vaccine) and Menveo (meningococcal ACWY). The deal made GSK the world's largest vaccines company, complementing its existing portfolio including Shingrix (in development at the time).
The vaccines market was dominated by GSK, Pfizer (Prevnar franchise), Merck (Gardasil, MMR), and Sanofi Pasteur. Adding Novartis's meningococcal vaccines gave GSK a stronger position in this high-margin, high-barrier segment. Bexsero became a blockbuster ($1.2B by 2019). The deal also created the GSK/Novartis consumer health JV (GSK 63.5%), which eventually became Haleon (spun off 2022).
GSK and Novartis announce historic asset swap: vaccines, oncology, and consumer healthcare JV.
GSK acquires Novartis vaccines (ex-flu) for $5.25B upfront + $1.8B milestones in three-part $16B asset swap.
GSK vaccines profit falls 31% in Q1 2015 vs prior year as integration challenges emerge.
Vaccines profit rebounds 30% in Q3 2015. Novartis vaccine sales exceed prior projections by 5x.
Former Novartis vaccine portfolio sales exceed original projections by 9x under GSK stewardship.
Initial profit plunge but GSK turned Novartis vaccines into standout performer exceeding forecasts by 9x.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Novartis AG (this deal) | 2014 | $16.0B | 76 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2014 deals · GSK plc deals · Oncology deals